9 METERS BIOPHARMA, INC. - FORM 10-K - EX-23.1 - EXHIBIT 23.1 - March 13, 2018

Attached files

file filename
EX-10.18 - EXHIBIT 10.18 - 9 METERS BIOPHARMA, INC.tv487458_ex10-18.htm
EX-32.2 - EXHIBIT 32.2 - 9 METERS BIOPHARMA, INC.tv487458_ex32-2.htm
EX-32.1 - EXHIBIT 32.1 - 9 METERS BIOPHARMA, INC.tv487458_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - 9 METERS BIOPHARMA, INC.tv487458_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - 9 METERS BIOPHARMA, INC.tv487458_ex31-1.htm
EX-21.1 - EXHIBIT 21.1 - 9 METERS BIOPHARMA, INC.tv487458_ex21-1.htm
EX-10.27 - EXHIBIT 10.27 - 9 METERS BIOPHARMA, INC.tv487458_ex10-27.htm
EX-10.26 - EXHIBIT 10.26 - 9 METERS BIOPHARMA, INC.tv487458_ex10-26.htm
EX-10.25 - EXHIBIT 10.25 - 9 METERS BIOPHARMA, INC.tv487458_ex10-25.htm
EX-10.24 - EXHIBIT 10.24 - 9 METERS BIOPHARMA, INC.tv487458_ex10-24.htm
EX-10.23 - EXHIBIT 10.23 - 9 METERS BIOPHARMA, INC.tv487458_ex10-23.htm
EX-10.22 - EXHIBIT 10.22 - 9 METERS BIOPHARMA, INC.tv487458_ex10-22.htm
EX-10.21 - EXHIBIT 10.21 - 9 METERS BIOPHARMA, INC.tv487458_ex10-21.htm
EX-10.20 - EXHIBIT 10.20 - 9 METERS BIOPHARMA, INC.tv487458_ex10-20.htm
EX-10.17 - EXHIBIT 10.17 - 9 METERS BIOPHARMA, INC.tv487458_ex10-17.htm
EX-10.14 - EXHIBIT 10.14 - 9 METERS BIOPHARMA, INC.tv487458_ex10-14.htm
EX-10.13 - EXHIBIT 10.13 - 9 METERS BIOPHARMA, INC.tv487458_ex10-13.htm
EX-10.12 - EXHIBIT 10.12 - 9 METERS BIOPHARMA, INC.tv487458_ex10-12.htm
EX-10.11 - EXHIBIT 10.11 - 9 METERS BIOPHARMA, INC.tv487458_ex10-11.htm
EX-10.4 - EXHIBIT 10.4 - 9 METERS BIOPHARMA, INC.tv487458_ex10-4.htm
EX-10.3 - EXHIBIT 10.3 - 9 METERS BIOPHARMA, INC.tv487458_ex10-3.htm
EX-10.2 - EXHIBIT 10.2 - 9 METERS BIOPHARMA, INC.tv487458_ex10-2.htm
EX-10.1 - EXHIBIT 10.1 - 9 METERS BIOPHARMA, INC.tv487458_ex10-1.htm
EX-4.1 - EXHIBIT 4.1 - 9 METERS BIOPHARMA, INC.tv487458_ex4-1.htm
EX-3.1 - EXHIBIT 3.1 - 9 METERS BIOPHARMA, INC.tv487458_ex3-1.htm
10-K - 10-K - 9 METERS BIOPHARMA, INC.tv487458_10k.htm

 

Exhibit 23.1

 

Consent of Independent Registered

 

Public Accounting Firm

 

We consent to the incorporation by reference in the registration statement on Form S-8 (File No. 333-215406) of our report, which includes an explanatory paragraph relating to the Company’s ability to continue as a going concern, dated March 12, 2018, on our audits of the consolidated financial statements of Monster Digital, Inc. and Subsidiaries as of December 31, 2017 and 2016 and for the years then ended, included in this Annual Report on Form 10-K of Innovate Biopharmaceuticals, Inc. (formerly Monster Digital, Inc.) for the year ended December 31, 2017.

  

/s/ CohnReznick LLP

 

Roseland, New Jersey

March 12, 2018      

 

 

 

9 METERS BIOPHARMA, INC. Reports